Retinal Disorders Treatment Market To Reach $44.5 Billion by 2035

Retinal disorders treatment market is projected to grow from $23.7 billion in 2025 to $44.5 billion by 2035, expanding at a CAGR of 6.5% during the forecast period (2026–2035). The market growth is primarily driven by the rising prevalence of vision impairment and retinal diseases, alongside advancements in biologics and gene-based therapies.

Browse the full report description of “Retinal Disorders Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Treatment, Surgical Treatment, Implantable Devices), By Disease Type (Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Detachment, Macular Edema, Inherited Retinal Diseases), By Technology (Biologics-Based Therapy, Gene Therapy, Cell Therapy, Sustained Drug Delivery Systems, Laser-Based Technologies), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Specialty Eye Institutes), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/retinal-disorders-treatment-market

Among the segments, Biologics-Based Therapy under Technology is emerging as the fastest-growing segment due to its high efficacy in treating retinal diseases. Anti-VEGF therapies dominate this category, offering improved visual outcomes and reduced disease progression. Pharmaceutical companies are increasingly focusing on long-acting biologics and sustained delivery systems to reduce treatment frequency and enhance patient compliance.

Increasing Cases of Visual Impairment Globally

A key macro driver fueling market expansion is the increasing burden of visual impairment. According to the World Health Organization (WHO), over 2.2 billion people globally suffer from vision impairment or blindness, with retinal disorders such as age-related macular degeneration (AMD) and diabetic retinopathy being major contributors. This growing patient pool is directly boosting demand for retinal treatment solutions, particularly pharmacological therapies.

From an end-user perspective, hospitals and ophthalmology clinics account for a significant share of treatment delivery. According to the OECD, healthcare expenditure across member countries averaged around 9.7% of GDP in recent years, highlighting increased investments in advanced treatment infrastructure. This trend supports the adoption of high-cost biologics and surgical procedures for retinal conditions.

Key Innovation Transforming the Retinal Disorders Treatment Market

Market players are actively implementing strategic initiatives to strengthen their positions. A few of the strategies are given below: -

• In December 2024, Sandoz received FDA approval for Enzeevu (aflibercept-abzv), a biosimilar interchangeable with Eylea, significantly expanding patient access to cost-effective biologic therapies.
• In April 2023, Regeneron Pharmaceuticals announced the successful submission of a supplemental Biologics License Application (sBLA) for a higher-dose aflibercept 8 mg, aimed at extending treatment intervals for patients with wet AMD.
• In January 2022, Roche (Genentech) launched Vabysmo, the first bispecific antibody for the eye, targeting both VEGF and Ang-2 pathways to improve vascular stability in retinal diseases.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o Treatment Type

o Disease Type
o Technology
o End User
o Competitive Landscape – Regeneron Pharmaceuticals, Roche (Genentech), Novartis AG, Bayer AG, AbbVie (Allergan), among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Retinal Disorders Treatment Market Segment

By Treatment Type

• Pharmacological Treatment
• Surgical Treatment
• Implantable Devices

By Disease Type

• Age-related Macular Degeneration (AMD)
• Diabetic Retinopathy
• Retinal Vein Occlusion (RVO)
• Retinal Detachment
• Macular Edema
• Inherited Retinal Diseases

By Technology

• Biologics-Based Therapy
• Gene Therapy
• Cell Therapy
• Sustained Drug Delivery Systems
• Laser-Based Technologies

By End User

• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers (ASCs)
• Specialty Eye Institutes

Global Retinal Disorders Treatment Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/retinal-disorders-treatment-market